Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial ☆
Titel:
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial ☆
Auteur:
Griesinger, F. Curigliano, G. Thomas, M. Subbiah, V. Baik, C.S. Tan, D.S.W. Lee, D.H. Misch, D. Garralda, E. Kim, D.-W. van der Wekken, A.J. Gainor, J.F. Paz-Ares, L. Liu, S.V. Kalemkerian, G.P. Houvras, Y. Bowles, D.W. Mansfield, A.S. Lin, J.J. Smoljanovic, V. Rahman, A. Kong, S. Zalutskaya, A. Louie-Gao, M. Boral, A.L. Mazières, J.